XFOR
X4 Pharmaceuticals Inc

3,540
Mkt Cap
$311.27M
Volume
617,090.00
52W High
$9.70
52W Low
$1.35
PE Ratio
-0.36
XFOR Fundamentals
Price
$4.23
Prev Close
$3.56
Open
$3.75
50D MA
$3.67
Beta
1.51
Avg. Volume
575,084.86
EPS (Annual)
-$5.59
P/B
1.45
Rev/Employee
$17,881.12
$123.53
Loading...
Loading...
News
all
press releases
X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +38.89% and +53.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9h ago
News Placeholder
More News
News Placeholder
X4 Pharmaceuticals (XFOR) Projected to Post Quarterly Earnings on Tuesday
X4 Pharmaceuticals (NASDAQ:XFOR) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 24. (View Earnings Report at...
MarketBeat·15h ago
News Placeholder
X4 Pharmaceuticals, Inc. $XFOR Shares Acquired by Kingdon Capital Management L.L.C.
Kingdon Capital Management L.L.C. increased its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 300.0% in the third quarter, according to the company in its most recent Form 13F...
MarketBeat·1d ago
News Placeholder
Rosalind Advisors Inc. Makes New Investment in X4 Pharmaceuticals, Inc. $XFOR
Rosalind Advisors Inc. acquired a new stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) in the third quarter, according to its most recent filing with the Securities and...
MarketBeat·4d ago
News Placeholder
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -12.50% and -36.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Guggenheim Initiates Coverage on X4 Pharmaceuticals (NASDAQ:XFOR)
Guggenheim initiated coverage on shares of X4 Pharmaceuticals in a report on Monday. They issued a "buy" rating and a $12.00 price objective for the company...
MarketBeat·8d ago
News Placeholder
Vericel Corporation (VCEL) Matches Q4 Earnings Estimates
Vericel (VCEL) delivered earnings and revenue surprises of +0.74% and +1.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Recommendation of "Hold" by Brokerages
Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have earned a consensus rating of "Hold" from the five ratings firms that are covering the stock, Marketbeat reports. One investment...
MarketBeat·21d ago
News Placeholder
X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan
X4 Pharmaceuticals (NASDAQ:XFOR) Executive Chair Adam Craig said the company's near-term focus is centered on advancing mavorixafor in chronic neutropenia, as the company seeks to position itself as...
MarketBeat·30d ago
News Placeholder
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of "Hold" by Analysts
Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) have been given a consensus recommendation of "Hold" by the five research firms that are currently covering the firm, MarketBeat.com...
MarketBeat·2mo ago
<
1
2
...
>

Latest XFOR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.